Detection of HBV DNA by PCR and its application in clinical transfusion
Keywords:
Hepatitis B virus, HBsAg, Serological markers, Screening
Abstract
This study was done in order to detect the hepatitis B virus (HBV) DNA copies in patients through blood transfusions; recessive carriers with HBsAg negative but HBV DNA positive were further studied to see the content and distribution of HBV in patients, and provide evidence for the clinical treatment. A total of 532 blood samples collected from July 2014 to July 2015 were tested for HBV-DNA viral load and hepatitis B serological markers using quantitative Polymerase Chain Reaction (qPCR) and serologic test (the five serological markers of hepatitis B). The results showed that, 3 cases were HBV serology negative and the HBV-DNA viral load was in the range of 250–500 whereas only 1 case was HBsAb positive and the HBV-DNA viral load was in the range of 500 and above. Quantitative PCR, for detecting HBV DNA, together with serological routine test can effectively reduce the risk of transfusion and prevent medical disputes.References
1. Rawat S, Sharma N, Kumar M, Ahmed NK, Sailwal S, et al. Quantification of HBV DNA and its impact on viral load monitoring. JBPRAU 2013; 2(4): 75–80.
2. Wong DKH, Huang FY, Lai CL, Poon RTP, Seto WK, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatol 2011; 54(3): 829–836. doi: 10.1002/hep.24551.
3. Lusida MI, Nugrahaputra VE, Soetjipto, Handajani R, Nagano-Fujii M, et al. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J Clin Microbiol 2008; 46(7): 2160–2166. doi: 10.1128/JCM.01681–07.
4. Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infection in Korean blood donors. Transfus 2011; 51(8): 1840–1846. doi: 10.1111/j.1537–2995.2010.03056.x.
5. Huang J, Liu S, Zhang J, Peng L, Li Q, et al. Blood HBV, HCV and HIV nucleic acid detection in clinical transfusion: Application of NAT testing for HBV, HCV and HIV in clinical blood transfusion. Chin J Clin Hematol 2013; (1): 95–97.
2. Wong DKH, Huang FY, Lai CL, Poon RTP, Seto WK, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatol 2011; 54(3): 829–836. doi: 10.1002/hep.24551.
3. Lusida MI, Nugrahaputra VE, Soetjipto, Handajani R, Nagano-Fujii M, et al. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J Clin Microbiol 2008; 46(7): 2160–2166. doi: 10.1128/JCM.01681–07.
4. Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infection in Korean blood donors. Transfus 2011; 51(8): 1840–1846. doi: 10.1111/j.1537–2995.2010.03056.x.
5. Huang J, Liu S, Zhang J, Peng L, Li Q, et al. Blood HBV, HCV and HIV nucleic acid detection in clinical transfusion: Application of NAT testing for HBV, HCV and HIV in clinical blood transfusion. Chin J Clin Hematol 2013; (1): 95–97.
Published
2017-01-19
Issue
Section
Original Research Article
Copyright (c) 2016 Li Shunqing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
